GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials

Food and Healthcare Press Releases Monday June 29, 2020 09:24
Bangkok--29 Jun--ABM Connect
Clover Biopharmaceuticals initiates phase 1 study using GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SBC-2019

GSK’s scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover today announced the initiation of a Phase 1 clinical study evaluating the company’s COVID-19 S-Trimer vaccine (SCB-2019) in combination with GSKs pandemic adjuvant system.

The study initiation follows promising preclinical results which demonstrated the beneficial effect of GSKs pandemic adjuvant for the SCB-2019 vaccine candidate, with high neutralizing antibody levels elicited in multiple animal species.

Preliminary safety and immunogenicity results for the Phase 1 study are expected in August 2020. In parallel, the planning for a global Phase 2b/3 vaccine efficacy trial has begun, with initiation targeted later in 2020.

The use of an adjuvant is of particular importance in a pandemic situation since it can reduce the amount of protein required per dose, allowing more vaccine doses to be produced and made available to more people.

GSK has announced several scientific collaborations globally to develop adjuvanted COVID-19 vaccines. GSK expects further studies to begin across the range of its collaborations, including with Sanofi, later this year.

Thomas Breuer, Chief Medical Officer, GSK Vaccines, said: “Our deliberate approach is to combine our proven pandemic adjuvant technology with protein-based COVID-19 vaccine candidates from several collaborators. We believe this holds the promise to produce vaccines at scale, potentially benefiting billions of people. We are encouraged by the pre-clinical data of this adjuvanted COVID-19 vaccine candidate from Clover and look forward to reviewing the data from this first trial. If this trial is successful, we hope to be in a position to move into more advanced trials later in the year.”

Clover Biopharmaceuticals is a China-based, global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases, as well as viral vaccines. The research collaboration between GSK and Clover to develop a COVID-19 vaccine candidate was announced on 24th February 2020.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GSK is the leading manufacturer of vaccines globally. For further information please visit www.gsk.com


Latest Press Release

Merck Opens its Largest M Lab(TM) Collaboration Center in Shanghai

-- Integrated lab with customizable solutions, validation services, training and hands-on applications -- Shanghai center is newest and largest addition to Merck's global network of nine M Lab(TM) Collaboration Centers Merck, a leading science and...

Laboratory Studies Confirm BETADINE(R) Antiseptic Products' Effectiveness Against COVID-19 Virus

Mundipharma today announced that laboratory testing at the Duke-NUS Medical School in Singapore, has confirmed the effectiveness of its BETADINE(R) antiseptic products against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease. Testing has...

How to Sleep Better? Follow These 6 Tips to Get Quality Rest

COVID-19 has changed the lives of people everywhere. Many are working from home and trying to stay connected with colleagues and loved ones through technology. Almost everyone has had their normal routines upset in one way or another, and sleeping...

การประชุมวิชาการโภชนาการแห่งชาติ ครั้งที่ 14 "ชิวิตวิถีใหม่ สู้ภัยโควิด-19 ด้วยอาหารและโภชนาการ"

The 14th Thailand Congress of Nutrition (TCN 2020) "New Normal for Fighting COVID-19 with Food and Nutrition" วันที่ 7-8 ตุลาคม 2563 เนื้อหาที่น่าสนใจ โควิด-19 กับความมั่นคงด้านอาหาร และโภชนาการวิกฤตโควิด-19 ต่อสุขภาพ...

Apollo Proton Cancer Centre Receives Prestigious JCI Accreditation

Apollo Proton Cancer Centre (APCC), the first Proton Therapy Centre in South Asia and the Middle East, announced its accreditation by Joint Commission International (JCI), the recognized global leader in health care accreditation. This makes APCC the...

Related Topics